caa a22 4500 477072607 CHVBK 20180405111430.0 cr unu---uuuuu 170330e19961101xx s 000 0 eng 10.1007/BF00050999 doi (NATIONALLICENCE)springer-10.1007/BF00050999 Hemodynamic effects of intravenous elgodipine in coronary artery disease during rest and exercise, and basic pharmacokinetic parameters [Elektronische Daten] [Bernard Silke, Stephan de la Motte, P. Spiers, N. Herity, M. Drake, John Kelly, Francisco Harrison] Summary: Using an echo-Doppler method (Quantascope), the hemodynamic profile of the calcium channel antagonist elgodipine (64 μg/kg, iv) was investigated in 22 patients with angina pectoris at rest and during exercise. A placebo control was used. At rest, elgodipine significantly decreased systemic vascular resistance as well as systolic and diastolic blood pressure, while increasing cardiac output and stroke volume. During supine bicycle exercise at constant workload, elgodipine significantly increased cardiac output and stroke volume, and decreased the rate-pressure-product (double product); the exercise systolic blood pressure was decreased without change in the diastolic component. Elgodipine significantly reduced the incidence and severity (self-rated pain score) of exercise-induced anginal symptoms. Heart rate was not affected by elgodipine, either at rest or during exercise. In particular, no negative inotropy could be inferred from the echo-Doppler data. In the elgodipine plasma concentration profile (HPLC), three phases of elimination with half-life times of less than 1 hour, between 3 and 7 hours, and between 10 and 24 hours may be distinguished, indicating a "shallow” and a "deep” compartment. The hemodynamic data indicate an intermediate pharmacodynamic profile of elgodipine, lying between that of other dihydropyridines and that of compounds such as verapamil or diltiazem. Kluwer Academic Publishers, 1996 elgodipine nationallicence calcium channel antagonist nationallicence coronary artery disease nationallicence haemodynamics nationallicence exercise nationallicence pharmacokinetics nationallicence Silke Bernard Department of Therapeutics & Pharmacology, The Queen's University of Belfast, Belfast, UK aut de la Motte Stephan Harrison Clinical Research, Munich, Germany aut Spiers P. Department of Therapeutics & Pharmacology, The Queen's University of Belfast, Belfast, UK aut Herity N. Department of Therapeutics & Pharmacology, The Queen's University of Belfast, Belfast, UK aut Drake M. Department of Therapeutics & Pharmacology, The Queen's University of Belfast, Belfast, UK aut Kelly John The Institute of Biopharmaceuticals, Athlone, Eire aut Harrison Francisco Harrison Clinical Research, Munich, Germany aut Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10/5(1996-11-01), 573-580 0920-3206 10:5<573 1996 10 10557 https://doi.org/10.1007/BF00050999 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00050999 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Silke Bernard Department of Therapeutics & Pharmacology, The Queen's University of Belfast, Belfast, UK aut NATIONALLICENCE 700 1- de la Motte Stephan Harrison Clinical Research, Munich, Germany aut NATIONALLICENCE 700 1- Spiers P. Department of Therapeutics & Pharmacology, The Queen's University of Belfast, Belfast, UK aut NATIONALLICENCE 700 1- Herity N. Department of Therapeutics & Pharmacology, The Queen's University of Belfast, Belfast, UK aut NATIONALLICENCE 700 1- Drake M. Department of Therapeutics & Pharmacology, The Queen's University of Belfast, Belfast, UK aut NATIONALLICENCE 700 1- Kelly John The Institute of Biopharmaceuticals, Athlone, Eire aut NATIONALLICENCE 700 1- Harrison Francisco Harrison Clinical Research, Munich, Germany aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10/5(1996-11-01), 573-580 0920-3206 10:5<573 1996 10 10557 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer